SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Grainne who wrote (970)1/7/1998 12:28:00 AM
From: far east  Read Replies (2) | Respond to of 1359
 
I talked to Interneuron's Investors' Relations person, Ms. Tammy Bishop this morning. She has confirmed the fact that CerAxone is put on fast track review status by FDA. This is a super good news. As far as I know, FDA has yet to disapprove an fast-track reviewed drug. Also, it shortened significantly the approval time from 2 years to just 6 month away. I think this company will go significantly when the news hit the wire.

Go IPIC


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News